HanAll Advancing Novel Dry Eye Contender Despite Mixed Top-Line
First Phase III Trial Misses Primary Endpoint
HanAll and Daewoong remain upbeat on dry eye candidate HL036 and are gearing up for a second Phase III US study despite the first missing its primary endpoint in just-released top-line results.
You may also be interested in...
A mixed set of results from a Phase IIb/III trial of TOP1630 has not deterred the privately-held firm which maintains that the anti-inflammatory kinase inhibitor is a promising treatment.
As widely anticipated, Takeda has reached an agreement to divest an ex-Shire ophthalmology drug, as it streamlines the combined post-acquisition business to focus on core therapeutic pillars.
The FDA is requiring an additional RGN-259 Phase III trial to further show efficacy in both signs and symptoms of dry eye in a larger patient population.